BMJ report date: May 19, 2026 [Source: bmj.com/content/393/bmj-2026-597166] Health Canada first generic authorization: April 28, 2026 [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html] Dr
It's not hypereal users validate steady, sustainable results
We like the tolerability profile of that mechanism, but we are interested in building that out further. This is a clear signal to the market that their current $2.3B deal with Gubra (for an Amylin agonist) is just the foundation, and they are actively looking for additional assets, most likely a GLP-1, to create a CagriSema-like combination therapy
VIEW SEMAGLUTIDE Ozempic Ozempic is a brand-name formulation, approved by the FDA for the management of type 2 diabetes and weight control
When somebody's 350 pounds, they are not getting down to a weight that's healthy with medication
Especially, their analgesic effects are achieved without the development of tolerance, offering a significant advantage over traditional pain management strategies